^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Anaplastic Astrocytoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pilot study of nivolumab in pediatric patients with hypermutant cancers.
Published date:
05/19/2021
Excerpt:
...6 male and 5 female patients aged 9-18 yrs received treatment with NIVO...3pts had TMB 5-10mut/Mb, 5pts had TMB > 10mut/Mb (range 14-837, median 64), 3 pts enrolled on basis of RRD....This pilot study showed evidence of impressive clinical benefit particularly for relapsed GBM/AA patients for whom median survival is typically ̃6 months...
DOI:
10.1200/JCO.2021.39.15_suppl.10011
